Marseille, Sept. 15, 2021 (GLOBE NEWSWIRE) —
- First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2
- New pre-clinical data…
